Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yaupon Therapeutics
This is a multi-center, open-label study of patients with previously treated stage I (IA and IB) or IIA MF who have not received a complete response after completing 12 months of treatment in clinical trial (2005NMMF-201-US)to either 0.02% MCH PG or 0.02% MCH in Aquaphor (AP) ointment formulations.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have completed the treatment phase of the Yaupon Therapeutics-sponsored Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not achieved a complete response.
You may not be if
Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception
